Proactiveinvestors United Kingdom ANGLE PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom ANGLE PLC RSS feed en Sun, 26 May 2019 22:15:30 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - ANGLE's Parsortix device plays critical role in ground-breaking research on cancer spread ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13114/angle-s-parsortix-device-plays-critical-role-in-ground-breaking-research-on-cancer-spread-13114.html Fri, 26 Apr 2019 11:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13114/angle-s-parsortix-device-plays-critical-role-in-ground-breaking-research-on-cancer-spread-13114.html <![CDATA[News - ANGLE device aids ground-breaking research on cancer spread ]]> https://www.proactiveinvestors.co.uk/companies/news/219151/angle-device-aids-ground-breaking-research-on-cancer-spread-219151.html ANGLE PLC’s (LON:AGL) liquid biopsy system has been deployed in ground-breaking research assessing the role of the body’s own immune suppressor cells in promoting the cancer spread – a process called metastasis.

The company’s Parsortix device proved efficient at harvesting circulating tumour cell clusters and was superior to the competing method of collection on two levels: the size of the cluster and Parsortix’s ability to successfully extract these large clusters 100% of the time.

Researchers looked at metastatic breast and melanoma cancers to assess the role of myeloid-derived suppressor cells, which are part of clusters identified by the ANGLE device.

Clusters vs singles

It emerged that large circulating tumour cell clusters were fifty-times more likely to generate metastasis than single circulating tumour cells.

The work was carried out by a team led by Professor Dario Marchetti at the Biomarker Research Program at the Houston Methodist Research Institute in tandem with members of the Center for Precision Health at the University of Texas and MD Anderson Cancer Center.

The results were published in a peer-reviewed publication called the International Journal of Molecular Sciences.

The study is just the latest example of Parsortix being an integral part of research into the mechanics behind cancer and the elements driving its spreads.

Experts believe ultimately the technology could allow doctors to take an almost personalised approach to the treatment of the disease.  

ANGLE’s chief executive, Dr Andrew Newland, said: “Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."

In afternoon trading, shares in ANGLE were 4.4% higher at 71.50p.

In a note to clients, analysts at 'house' broker finnCap reiterated a 110p target price on ANGLE and commented; "Not only does this further differentiate Parsortix from other CTC capture systems, but it also complements the current FDA breast cancer study, given that CTC clusters were taken from breast and melanoma cancer patients and should enhance CTC cluster research-led revenues of Parsortix.

"We expect ANGLE to submit Parsortix for FDA clearance in mid-2019, which should result in the first FDA cleared instrument for harvesting CTCs around the year-end."   -- Adds share price, analyst comment -- ]]>
Fri, 26 Apr 2019 07:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219151/angle-device-aids-ground-breaking-research-on-cancer-spread-219151.html
<![CDATA[RNS press release - IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190426070008_14052748/ Fri, 26 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190426070008_14052748/ <![CDATA[News - ANGLE shares rise 11% after its tumour cell detection device is deployed in cancer advance ]]> https://www.proactiveinvestors.co.uk/companies/news/218824/angle-shares-rise-11-after-its-tumour-cell-detection-device-is-deployed-in-cancer-advance-218824.html Shares in ANGLE PLC (LON:AGL) (OTCQX:ANPCY) rose 11% after it said its liquid biopsy system was used to assess the metastatic potential of breast cancer.

Metastasis is the process by which cancer spreads from its primary location.

READ: ANGLE ground-breaking liquid biopsy to be used in lung cancer study

Parsortix was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer. Researchers at the University of Texas MD Anderson Cancer Center then used a new technique called transmembrane receptor dynamics to distinguish between invasive cancer cells and less-invasive cells.

Being able to make such a distinction would allow doctors to offer more personalised treatments to patients.

The latest work by the team at the MD Anderson Cancer Center was published in the prestigious academic journal Nature.

"This study is the 19th peer-reviewed publication by a leading independent cancer centre demonstrating successful use of ANGLE's world leading Parsortix CTC system,” said the company’ chief executive, Andrew Newland.

“We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities."

Broker finnCap said the peer-reviewed article provided “further independent endorsement of the utility of Parsortix”.

The shares were trading 7.5p higher at 76p.

---adds broker quote and share pric---

]]>
Thu, 18 Apr 2019 07:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218824/angle-shares-rise-11-after-its-tumour-cell-detection-device-is-deployed-in-cancer-advance-218824.html
<![CDATA[RNS press release - Parsortix used in new cancer assessment technique ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190418070008_14045574/ Thu, 18 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190418070008_14045574/ <![CDATA[News - ANGLE ground-breaking liquid biopsy to be used in lung cancer study ]]> https://www.proactiveinvestors.co.uk/companies/news/218472/angle-ground-breaking-liquid-biopsy-to-be-used-in-lung-cancer-study-218472.html ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) ground-breaking liquid biopsy system will be incorporated into a clinical study to provide an early warning of relapse among patients being treated for non-small cell lung cancer.

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group and will be deployed to track circulating tumour DNA, fragments of dead cancer cells and circulating tumour cells (CTCs).

A total of 50 operable early-stage patients will have blood drawn prior to surgery, one month after the operation and then every three to six months until relapse. 

CTC evaluation is being undertaken by the University of Athens, lead by Professor Evi Lianidou, and the latest collaboration builds on work by the same team using Parsortix in research on head and neck cancer.

 "This is another example of ANGLE's product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer,” said ANGLE chief executive Andrew Newland. 

“The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for ANGLE."

Shares in ANGLE held steady at 67p in late afternoon trading on Friday.

 -- Adds share price --

]]>
Fri, 12 Apr 2019 07:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218472/angle-ground-breaking-liquid-biopsy-to-be-used-in-lung-cancer-study-218472.html
<![CDATA[RNS press release - LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190412070006_14038627/ Fri, 12 Apr 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190412070006_14038627/ <![CDATA[News - ANGLE’s Parsortix liquid biopsy getting lots of exposure at world’s biggest cancer conference ]]> https://www.proactiveinvestors.co.uk/companies/news/217938/angles-parsortix-liquid-biopsy-getting-lots-of-exposure-at-worlds-biggest-cancer-conference-217938.html ANGLE PLC’s (LON:AGL) Parsortix cancer detection system has been showcased by a number of customers at the world’s largest cancer research conference in Atlanta, US.

The University of Athens, Northwestern University and the National Tumour Institute of Milan all presented posters featuring Parsortix at the American Association for Cancer Research (AACR) conference.

Work by the University of Athens was particularly important, ANGLE said, as it demonstrated the “superior performance” of Parsortix in head and neck squamous cell carcinoma (HNSCC) versus antibody-based approaches.

READ: ANGLE’s Parsortix liquid biopsy proving to be more than just a cancer detection device

Several cancer drugs, including Bristol Myers-Squibb’s Opdivo and Merck’s Keytruda, work best in patients with high levels of PD-L1 expression.

In the UoA’s studies, Parsortix was found to be twice as effective at identifying patients with PD-L1 expression.

From a group of 50, Parsortix identified nine with PD-L1 expression whereas the antibody-based test only identified four.

Around one in five patients typically respond to PD-L1 immunotherapies so the Parsortix result was consistent with expected detection levels.

“The multiple poster presentations by ANGLE and its customers at AACR demonstrate new potential applications for ANGLE's Parsortix system and further builds the third-party evidence that Parsortix is a market-leading CTC liquid biopsy solution,” said chief executive Andrew Newland.

“The successful detection of PD-L1 in head and neck cancer opens the potential for collaboration with leading pharma companies with FDA cleared immunotherapy drugs.”

]]>
Thu, 04 Apr 2019 07:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217938/angles-parsortix-liquid-biopsy-getting-lots-of-exposure-at-worlds-biggest-cancer-conference-217938.html
<![CDATA[RNS press release - AACR 2019 ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190404070005_14028176/ Thu, 04 Apr 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190404070005_14028176/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190311070011_13996486/ Mon, 11 Mar 2019 07:00:11 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190311070011_13996486/ <![CDATA[News - ANGLE passes key milestone recruitment is completed for phase III clinical trial of its liquid biopsy system ]]> https://www.proactiveinvestors.co.uk/companies/news/215973/angle-passes-key-milestone-recruitment-is-completed-for-phase-iii-clinical-trial-of-its-liquid-biopsy-system-215973.html ANGLE PLC (LON:AGL, OTCQX:ANPCY) said it had passed a “key milestone” following the completion of recruitment to a phase III clinical study to assess the potential of its liquid biopsy in metastatic breast cancer.

A total of 400 people will be screened using the Parsortix system, which harvests tumour cells. The work is being carried out at world-leading cancer centres in Texas, California and Illinois.

READ: “Significant milestone” for ANGLE as it kicks off second ovarian cancer study

Results from the trial will be submitted to the Food & Drug Administration by mid-year as planned.

However, ANGLE cautioned that the timeline, once the FDA has received all the data, is uncertain as researchers are following a completely new protocol for an entirely unique product – in other words, the regulator doesn’t have an established blueprint or tick-sheet to follow.

Chief executive Andrew Newland said: “We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer."

]]>
Thu, 07 Mar 2019 07:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215973/angle-passes-key-milestone-recruitment-is-completed-for-phase-iii-clinical-trial-of-its-liquid-biopsy-system-215973.html
<![CDATA[RNS press release - ENROLMENT COMPLETE FOR FDA CLINICAL STUDY ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190307070013_13993141/ Thu, 07 Mar 2019 07:00:13 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190307070013_13993141/ <![CDATA[News - “Significant milestone” for ANGLE as it kicks off second ovarian cancer study ]]> https://www.proactiveinvestors.co.uk/companies/news/215497/significant-milestone-for-angle-as-it-kicks-off-second-ovarian-cancer-study-215497.html ANGLE PLC (LON:AGL) has kicked off another clinical study of Parsortix – its simple blood test which can help doctors spot the early signs of cancer.

In a similar study last year, Parsortix demonstrated a correct prediction of cancer of 95.1% with higher sensitivity and specificity (or fewer false positives) than any other test available for the same application.

READ: Researchers find new use for ANGLE’s Parsortix

Since then, ANGLE has been optimising the liquid biopsy which it hopes will further improve the accuracy this time around.

To start with, 70 patients with a pelvic mass will be tested to see if the lump is cancerous or not. This will then be followed by a 200-subject clinical study.

The first subjects have already been enrolled and ANGLE expects the study to complete in the first quarter of 2020.

Should the results confirm Parsortix’s accuracy in screening for cancers, ANGLE plans to begin partnering discussions with large clinical laboratories and women’s health companies.

ANGLE would then use the partner’s sales and distribution channels to scale deployment of its device.

Boss ‘very excited’

“The planned 200-subject study is designed to verify the clinical performance of the novel ANGLE ovarian cancer assay in discriminating malignant from benign pelvic masses prior to surgery,” said Richard Moore, the director of the Gynecologic Oncology Division at the University of Rochester Medical Center Wilmot Cancer Institute.

“The test's high sensitivity and specificity, demonstrated in a previous study presented at the 2018 SGO annual meeting, will help to ensure that women with ovarian cancer get the best possible specialist treatment whilst women with a benign condition will be able to have their treatment locally with the physicians they know.”

ANGLE founder and chief executive Andrew Newland added: “The performance of the HyCEAD Ziplex system in conjunction with Parsortix endorses the company's decision to acquire the platform and opens a wide range of commercial opportunities.

“The first clinical application in ovarian cancer is an exemplar with a large opportunity for ANGLE and we are excited about progressing the clinical verification study.”

Significant milestone, says broker

“This [study] is a significant milestone and in line with comments made at its interim results in January,” said finnCap analyst Mark Brewer.

“We reiterate our 110p price target and await eagerly for confirmation that the FDA breast cancer study has completed enrolment, expected in Q1 2019.”

ANGLE shares were unchanged at 54.5p in early deals on Thursday.

]]>
Thu, 28 Feb 2019 08:19:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215497/significant-milestone-for-angle-as-it-kicks-off-second-ovarian-cancer-study-215497.html
<![CDATA[RNS press release - FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190228070022_13984463/ Thu, 28 Feb 2019 07:00:22 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190228070022_13984463/ <![CDATA[News - ANGLE: Researchers find new use for company's cancer cell harvesting device ]]> https://www.proactiveinvestors.co.uk/companies/news/215192/angle-researchers-find-new-use-for-company-s-cancer-cell-harvesting-device-215192.html Using ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) liquid biopsy has been revealed to result in a 30-fold increase in tumour cells harvested for analysis in cancer patients.

Parsortix was deployed by a Düsseldorf team called Disseminated Cancer Cell Network.

READ: ANGLE technology used in cutting-edge research featured in science journal Nature

The researchers and clinicians were attempting to enhance a technique called diagnostic leukapheresis, which harvests circulating tumour cells (CTCSs) to assess how to better treat patients individually.

The increase in the number of CTCs captured by Parsortix was highly effective in reducing the “background” produced by white blood cells caught during the process.

“The Parsortix system provides an easy solution for enriching the sample and harvesting these CTCs keeping the cells alive and undamaged,” said researcher Dr Hans Neubauer.

“The workflow we have developed to culture these cells will allow an intensification of research into new diagnostic and therapeutic solutions."

The results from the work carried out by the Disseminated Cancer Cell Network were peer-reviewed

and published in the periodical Clinical Chemistry. Click here to read.

  

]]>
Mon, 25 Feb 2019 07:57:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215192/angle-researchers-find-new-use-for-company-s-cancer-cell-harvesting-device-215192.html
<![CDATA[RNS press release - CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190225070006_13979565/ Mon, 25 Feb 2019 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190225070006_13979565/ <![CDATA[News - ANGLE technology used in cutting-edge research featured in science journal Nature ]]> https://www.proactiveinvestors.co.uk/companies/news/214337/angle-technology-used-in-cutting-edge-research-featured-in-science-journal-nature-214337.html ANGLE PLC (LON:AGL), the med-tech firm at the forefront of cancer research, said its liquid biopsy system has been used in research featured in the prestigious science journal Nature.

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland, which highlighted the role of immune cells assigned to protect the body from the disease in actually promoting the spread of cancer - a process called metastasis.

READ: ANGLE on track to complete key Parsortix study in current quarter

The research published in Nature identified a subset of circulating tumour cell clusters using ANGLE's technology that was demonstrated to be associated with greatly increased metastatic ability.

Understanding the role of the patient’s own immune system in aiding cancer spread opens the potential for the development of new therapies that impede the process.

"Research into CTC clusters using the Parsortix system has the potential to change the way that cancer is treated,” said ANGLE founder and chief executive Andrew Newland.

“The publication of the University of Basel's research in Nature on CTC-neutrophil clusters, following the previous publication in Cell, is a tremendous achievement for Basel, one of ANGLE's leading customers.

“We are delighted that the harvesting of CTC clusters, using the Parsortix system, is a key element in the drive to block the process of cancer metastasis that is responsible for over 90% of deaths from cancer."

]]>
Mon, 11 Feb 2019 07:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214337/angle-technology-used-in-cutting-edge-research-featured-in-science-journal-nature-214337.html
<![CDATA[RNS press release - Research into role of immune cells in cancer ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190211070005_13964083/ Mon, 11 Feb 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190211070005_13964083/ <![CDATA[News - ANGLE on track to complete key Parsortix study in current quarter ]]> https://www.proactiveinvestors.co.uk/companies/news/213690/angle-on-track-to-complete-key-parsortix-study-in-current-quarter-213690.html ANGLE PLC (LON:AGL) expects to complete the clinical study of its Parsortix cancer detection technology by the end of March this year.

So far, 369 of the required 400 patients – 200 with breast cancer and 200 healthy – have been enrolled in the study.

READ: ANGLE device has lymph node potential, says German research team

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the “continued progress” to date, ANGLE remains confident in wrapping up the trial and data analysis in the current quarter.

“The first half of the year has been one of continued progress by ANGLE and we look forward to completing our FDA clinical and analytical studies in metastatic breast cancer in the US in Q1 2019 with only 31 more subjects to recruit,” said chairman Garth Selvey.

Ovarian cancer test progressing well

In the same update, the AIM company confirmed that the pre-study of an ovarian cancer test, which combines Parsortix with its HyCEAD Ziplex analysis platform, is due to start in the current quarter, subject to ethics approval.

“Significant progress has also been achieved in the optimisation of our recently acquired HyCEAD Ziplex platform for downstream analysis in preparation for our ovarian cancer clinical verification study,” added chairman Selvey.

Healthy cash balance

In the six months ended 31 October, revenue and grant income totalled £0.4mln (H1 17/18: £0.2mln).

Loss from continuing operations widened to £4.2mln (H1 17/18: £3.4mln) reflecting planned investment.

Following a £12.7mln fundraise back in June, ANGLE ended the half with £14.9mln in the bank (April 2018: £7.6mln).

]]>
Thu, 31 Jan 2019 08:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213690/angle-on-track-to-complete-key-parsortix-study-in-current-quarter-213690.html
<![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190131070009_13952734/ Thu, 31 Jan 2019 07:00:09 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190131070009_13952734/ <![CDATA[News - ANGLE device has lymph node potential, says German research team ]]> https://www.proactiveinvestors.co.uk/companies/news/213485/angle--device-has-lymph-node-potential-says-german-research-team-213485.html ANGLE PLC’s (LON:AGL) shares rose on Friday as the firm revealed it has found a potential new application for its liquid biopsy.

Dr Bernhard Polzer and his team at the Fraunhofer Institute for Toxicology and Experimental Medicine, in Regensburg, Germany, found ANGLE’s Parsortix system streamlines the analysis of lymph nodes in melanoma.

WATCH: ANGLE's Parsortix device plays critical role in ground-breaking new cancer research

Not only that, the new process incorporating Parsortix is more sensitive to detecting the spread of the disease to the lymph node, “greatly improving the ability to undertake key molecular analysis on cancer”. 

“It is an added benefit that it also facilitates single cell analysis reducing costs,” said Polzer.

“We previously tried other CTC [circulating tumour cell] systems including antibody-based and membrane systems but these were not suitable for this process."

Polzer’s research has been published as a peer-reviewed publication in the International Journal of Cancer.

"This is another example of our leveraged approach with research customers delivering new applications for Parsortix,” said ANGLE chief executive Andrew Newland.

“There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types."

In late morning trading, shares in ANGLE were 8.2% higher at 59.50p.

 -- Adds share price --

]]>
Tue, 29 Jan 2019 08:02:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213485/angle--device-has-lymph-node-potential-says-german-research-team-213485.html
<![CDATA[RNS press release - NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190129070009_13949575/ Tue, 29 Jan 2019 07:00:09 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190129070009_13949575/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140558_13932369/ Fri, 11 Jan 2019 14:05:58 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140558_13932369/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140032_13932360/ Fri, 11 Jan 2019 14:00:32 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140032_13932360/ <![CDATA[Media files - ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11799/angle-plc-s-parsortix-device-plays-critical-role-in-ground-breaking-new-cancer-research-11799.html Fri, 11 Jan 2019 13:03:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11799/angle-plc-s-parsortix-device-plays-critical-role-in-ground-breaking-new-cancer-research-11799.html <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110538_13932118/ Fri, 11 Jan 2019 11:05:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110538_13932118/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110035_13932108/ Fri, 11 Jan 2019 11:00:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110035_13932108/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090527_13931827/ Fri, 11 Jan 2019 09:05:27 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090527_13931827/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090028_13931824/ Fri, 11 Jan 2019 09:00:28 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090028_13931824/ <![CDATA[News - ANGLE device central to new, ground-breaking cancer research ]]> https://www.proactiveinvestors.co.uk/companies/news/212375/angle-device-central-to-new-ground-breaking-cancer-research-212375.html ANGLE PLC (LON:AGL) has revealed its cancer detection device played an important role in research that may one day help prevent the spread of cancer around the body.

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters - a group of cancer and other cells tethered together as a single mass.

WATCH: ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

Once these clusters were identified, the Basel team, led by Professor Nicola Aceto, was able to treat them with repurposed drugs already on the market.

Eye-catching

Eye-catching was the fact that this approach led to a “near total elimination” of metastasis in animal models.

As most people will know, metastasis is where cancer spreads to other parts of the body via the bloodstream. It is responsible for more than 90% of all cancer-related deaths.  

The detail of the research undertaken by the Cancer Metastasis Laboratory was published Friday (Jan 11) as a peer-reviewed article in the prestigious journal, Cell.

ANGLE is seeking US Food & Drug Administration approval for Parsortix.

Ground-breaking

Chief executive, Andrew Newland, said: "The ground-breaking CTC cluster work undertaken over the last three years by the University of Basel, one of ANGLE's leading customers, highlights completely new clinical uses for the Parsortix system with the potential to play a central role in dramatically improving patient outcomes.

“This is a key potential application for Parsortix liquid biopsy once we receive FDA clearance.

“Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."

---Repeated from Thursday evening---

]]>
Fri, 11 Jan 2019 07:28:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212375/angle-device-central-to-new-ground-breaking-cancer-research-212375.html
<![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110164113_13931006/ Thu, 10 Jan 2019 16:41:13 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110164113_13931006/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110163602_13930995/ Thu, 10 Jan 2019 16:36:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110163602_13930995/ <![CDATA[RNS press release - BREAKTHROUGH CANCER RESEARCH USING PARSORTIX ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110160102_13930951/ Thu, 10 Jan 2019 16:01:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110160102_13930951/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190109070002_13928170/ Wed, 09 Jan 2019 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190109070002_13928170/ <![CDATA[News - ANGLE’s Parsortix liquid biopsy proving to be more than just a cancer detection device ]]> https://www.proactiveinvestors.co.uk/companies/news/211923/angles-parsortix-liquid-biopsy-proving-to-be-more-than-just-a-cancer-detection-device-211923.html  

What it does

ANGLE plc (LON:AGL, OTCQX:ANPCY) is the firm behind Parsortix – a simple blood test which can help doctors spot the signs of cancer at an early stage.

Blood tests – or liquid biopsies as they are known in the business – were all the rage at some of the world’s biggest cancer conferences in 2018, including the American Society of Clinical Oncology meeting in Chicago over summer.

READ: Liquid biopsies – the breakthrough cancer tests ANGLE is already developing READ: Scientists make big breakthrough with Parsortix

Parsortix is slightly to different to some of its rivals, though: rather than testing for fragments of dead cancer cells, it detects and captures circulating tumour cells (CTCs).

CTCs provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

This method is seen as more reliable because previous tests have shown that fragments of dead cancer cells are present in around a quarter of people over 65 who do not have cancer. CTCs, on the other hand, “give a complete picture”, because they can only be found in people with cancer.

ANGLE is currently taking its system through the clinic, and more than 90% of the required 400 patients have now been enrolled in the study.

Key clinical trial to complete in Q1

It is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

With the progress made so far, it expects the trial to be completed by the end of March.

“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis,” said chief executive and founder Andrew Newland.

“This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”

Foetal abnormalities

The cancer arena is where Parsortix is gaining the most traction currently – more than 200 of its devices are in use around the world.

But ANGLE recently made a breakthrough when the system showed promise in harvesting foetal cells which could help detect abnormalities such as Down’s Syndrome in unborn children.

READ: ANGLE finds a new angle for Parsortix

In the small-scale study, Parsortix was able to distinguish between male and female chromosomes and, in one case, correctly identified trisomy 21, the marker for Down’s.

Parents and doctors are willing to pay a hefty price to ensure the health of their unborn babies, with the non-invasive prenatal testing market estimated to be worth around US$600mln. Analysts expect it to grow to US$1bn a year by 2022.

Ovarian cancer test progressing well, too

In the same update, the AIM company confirmed that the pre-study of an ovarian cancer test, which combines Parsortix with its HyCEAD Ziplex analysis platform, is due to start in the current quarter, subject to ethics approval.

“Significant progress has also been achieved in the optimisation of our recently acquired HyCEAD Ziplex platform for downstream analysis in preparation for our ovarian cancer clinical verification study,” added chairman Selvey.

Healthy cash balance

In the six months ended 31 October, revenue and grant income totalled £0.4mln (H1 17/18: £0.2mln).

Loss from continuing operations widened to £4.2mln (H1 17/18: £3.4mln) reflecting planned investment.

Following a £12.7mln fundraise back in June, ANGLE ended the half with £14.9mln in the bank (April 2018: £7.6mln).

]]>
Thu, 03 Jan 2019 09:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211923/angles-parsortix-liquid-biopsy-proving-to-be-more-than-just-a-cancer-detection-device-211923.html
<![CDATA[RNS press release - Issue of LTIP Options and Share Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181221070003_13912406/ Fri, 21 Dec 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181221070003_13912406/ <![CDATA[News - ANGLE names diagnostic pathology expert Dr Joseph D Khoury as a scientific advisor ]]> https://www.proactiveinvestors.co.uk/companies/news/210093/angle-names-diagnostic-pathology-expert-dr-joseph-d-khoury-as-a-scientific-advisor-210093.html ANGLE plc (LON:AGL) (OTCQX:ANPCY) has announced the appointment of Dr Joseph D Khoury as a scientific advisor to the company's established Scientific Advisory Board.

The AIM-listed liquid biopsy company pointed out that Khoury is a recognised expert in diagnostic pathology and has significant experience in the cytological and morphological analysis of cancer cells.

READ: ANGLE acquires remaining stake in US subsidiary from Parsortix inventor

It added that his expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system as the liquid biopsy platform of choice for harvesting and analysing circulating tumour cells and other rare cells from blood as a means of diagnosing and monitoring disease.

The group said Khoury is a tenured Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas and is the Executive Director of the MD Anderson Cancer Network for the Division of Pathology and Laboratory Medicine and the Director of the MD Anderson Institutional Immunohistochemistry Laboratory.

ANGLE founder and chief executive, Andrew Newland, commented: "Our Parsortix system has been shown to enable the efficient harvesting of circulating cancer cells and other rare cells in patient blood.

“Dr Khoury's expertise in interpreting these cells and their relevance to a patient's condition, and potentially their prognosis and treatment, is expected to open up new possibilities for the use of Parsortix system. “

]]>
Wed, 28 Nov 2018 07:31:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210093/angle-names-diagnostic-pathology-expert-dr-joseph-d-khoury-as-a-scientific-advisor-210093.html
<![CDATA[RNS press release - LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181128070008_13882757/ Wed, 28 Nov 2018 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181128070008_13882757/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181113171038_13865659/ Tue, 13 Nov 2018 17:10:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181113171038_13865659/ <![CDATA[News - ANGLE acquires remaining stake in US subsidiary from Parsortix inventor ]]> https://www.proactiveinvestors.co.uk/companies/news/208492/angle-acquires-remaining-stake-in-us-subsidiary-from-parsortix-inventor-208492.html ANGLE plc (LON:AGL) now owns 100% of its North American subsidiary after buying out Georgi Hvichia’s 9.47% stake.

Hvichia is the original inventor of ANGLE’s Parsortix cancer detection technology. As such, he still holds a stake in ANGLE North America (ANAI) but the company has issued £467,500 worth of shares to acquire it.

READ: ANGLE finds new angle for cancer detection device

It means that Hvichia, who is currently a director of ANAI but will move to a scientific advisory board member role, now owns 1.08mln ANGLE shares, around 0.76% of the total share capital.

The AIM-quoted firm said the agreement gives it a clean 100% ownership of all its group companies, adding that the US subsidiary is particularly important as it owns core intellectual property related to Parsortix.

“We are pleased to reach an agreement with Georgi Hvichia, the original inventor of the Parsortix microfluidic technology, to acquire his remaining shareholding in our US operating subsidiary in exchange for ANGLE plc shares,” said chief executive Andrew Newland.

Angle shares were untraded at 96.2p in early deals on Monday.

]]>
Mon, 05 Nov 2018 08:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208492/angle-acquires-remaining-stake-in-us-subsidiary-from-parsortix-inventor-208492.html
<![CDATA[RNS press release - Acquisition of outstanding shares ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181105070006_13854132/ Mon, 05 Nov 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181105070006_13854132/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181102140035_13853552/ Fri, 02 Nov 2018 14:00:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181102140035_13853552/ <![CDATA[RNS press release - Appointment of Dr Jan Groen as NED ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181101070005_13850480/ Thu, 01 Nov 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181101070005_13850480/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181030162150_13848238/ Tue, 30 Oct 2018 16:21:50 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181030162150_13848238/ <![CDATA[Media files - ANGLE PLC sees big opportunities in non-invasive prenatal testing ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11017/angle-plc-sees-big-opportunities-in-non-invasive-prenatal-testing-11017.html Mon, 29 Oct 2018 10:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11017/angle-plc-sees-big-opportunities-in-non-invasive-prenatal-testing-11017.html <![CDATA[News - ANGLE finds a new angle for cancer detection device as it screens pregnant women ]]> https://www.proactiveinvestors.co.uk/companies/news/207996/angle-finds-a-new-angle-for-cancer-detection-device-as-it-screens-pregnant-women-207996.html ANGLE plc(LON:AGL, OTCQX:ANPCY) said its device for detecting the early signs of cancer had shown promise harvesting fetal cells.

Parsortix appeared to score well against existing methods of non-invasive prenatal testing (NIPT).

Specifically, it was able to harvest intact cells, which could then be assessed for abnormalities such Down’s Syndrome.

Currently-available technology allows for only fragments of dead fetal cells to be collected, which limits the scope for testing an assessment.

Current technology has drawbacks

Parsortix, by contrast, could pave the way for broader genetic screening.

It is estimated that current cell-free fetal DNA non-invasive techniques identify less than 10% of all serious birth defects. 

“A test utilising intact fetal cells could have much wider application than the current cell-free tests,” ANGLE said.

A further limitation of the current method of non-invasive testing is that it relies on next-generation sequencing analysis of cell-free DNA.

This area is currently the domain of a small handful large life sciences companies which closely guard the intellectual property.

The Parsortix method has its own cell-free DNA analysis that doesn’t infringe the competition’s patents.

Presentation of data 

Data from the pilot study of 19 pregnant women will be presented at the Sixth Annual Advances in Prenatal Diagnostics conference in Cambridge, Massachusetts.

Delegates will hear that large fetal cells were identified in every case. 

The test was able to distinguish between male and female chromosomes and, in one case, correctly identified trisomy 21, the marker for Down’s.

“This was a small-scale pilot study and, whilst highly encouraging, substantial further work will be necessary to develop an effective NIPT [non-invasive] test,” ANGLE said. 

The size of the non-invasive prenatal testing market is estimated to be around US$600mln and is expected to grow to US$1bn a year by 2022.

Commercial opportunity

Recognising this, but unwilling to impede the current traction it is gaining for Parsortix in the cancer arena, ANGLE is looking for an outside partner to help commercialise the fetal cell test opportunity.

"Non-invasive prenatal testing is a major new market for the Parsortix system and a potential solution to the current limitations of NIPT, providing a more comprehensive diagnosis of fetal abnormalities for mothers at risk of an affected pregnancy,” said ANGLE founder and chief executive, Andrew Newland. 

“ANGLE's product-based approach to liquid biopsy enables us to leverage partnerships with third parties, which we are developing in the NIPT space, an established and fast growing large-scale market."

The shares rose 4%, valuing ANGLE at £58mln.

]]>
Mon, 29 Oct 2018 07:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/207996/angle-finds-a-new-angle-for-cancer-detection-device-as-it-screens-pregnant-women-207996.html
<![CDATA[RNS press release - PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181029070007_13845082/ Mon, 29 Oct 2018 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181029070007_13845082/ <![CDATA[News - Over 75% of patients now enrolled into ANGLE’s Parsortix clinical study ]]> https://www.proactiveinvestors.co.uk/companies/news/207826/over-75-of-patients-now-enrolled-into-angles-parsortix-clinical-study-207826.html ANGLE PLC (LON:AGL) continues to make “good progress” with the enrolment for the clinical study of its Parsortix cancer detection technology.

So far, over 75% of the required 400 patients – 200 with cancer and 200 healthy – have been enrolled in the study.

READ: Scientists make major breakthrough with Parsortix

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019.

Away from the trial, ANGLE has been carrying out more work of its own on Parsortix, which has yielded “new insights” into the system.

Multi-billion-dollar market

“Our significant and sustained efforts to complete the clinical and analytical studies needed to support our FDA submission are progressing well,” said chief executive Andrew Newland.

“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.”

He added: “This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”

Shares fell 4.4% to 41.1p.

]]>
Thu, 25 Oct 2018 08:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207826/over-75-of-patients-now-enrolled-into-angles-parsortix-clinical-study-207826.html
<![CDATA[RNS press release - Good Progress with FDA Studies ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181025070005_13841591/ Thu, 25 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181025070005_13841591/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181009070010_13820925/ Tue, 09 Oct 2018 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181009070010_13820925/